Who is sponsoring NCT05850728?

NCT05850728 is sponsored by University of Washington.

What condition does NCT05850728 study?

NCT05850728 studies Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy.

What is the status of NCT05850728?

NCT05850728 is currently COMPLETED.

Last reviewed 2024-12-11 · How we verify

First in Human Study of TLC-ART 101 (ACTU 2001)

NCT05850728 PHASE1 COMPLETED

This study is a prospective, open-label, single-site, first-in-human study of a long-acting, injectable combination antiretroviral therapy platform, with a pharmacologically-guided adaptive design for dose escalation, de-escalation, and study duration. The study is designed to learn whether the formulation can be used as a platform for other drugs for treatment of HIV. The formulation is a drug combination nanoparticle (DCNP). The study will be conducted by UW Positive Research. The sample size for this study is 12-16. The study population consists of healthy adults without HIV. The study duration is 57 days per participant at the start of the study.

Details

Lead sponsor	University of Washington
Phase	PHASE1
Status	COMPLETED
Enrolment	12
Start date	Sat Apr 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Human Immunodeficiency Virus
Treatment
Antiretroviral Therapy

Interventions

TLC-ART

Countries

United States